Mark Reisenauer & Hernani Oliveira
Mark Reisenauer is senior vice president, oncology business unit, Astellas. In this role, he is responsible for commercial activities supporting marketed products, Astellas' co-promotion partners and commercial planning for early stage oncology development compounds. Mark is a member of the Astellas U.S. Management Committee. Mark joined Astellas in 2011 as vice president, sales and marketing, oncology, where he led commercial activities supporting oncology products, Tarceva and the launch of Xtandi. Prior to joining Astellas, Mark served as senior vice president and chief commercial officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning and commercial launch planning. Previously, Mark held various sales and marketing leadership roles at Abbott, Pharmacia, Bristol-Myers Squibb and AstraZeneca. Mark experienced firsthand the complexity of navigating cancer care while his father battled head and neck cancer. After losing his father, he has dedicated his energy toward cancer care innovation. Mark earned a bachelor’s degree in political science from the University of Wisconsin.
In 2017, Hernâni Oliveira of Porto, Portugal won the Astellas Oncology C3 Grand Prize. The award-winning HOPE PROJECT consists of a two-part app developed to help pediatric cancer patients and their parents solve issues related to medication adherence and the sedentary lifestyle of children who are diagnosed with cancer, as well as help parents further understand and explain complex cancer treatment procedures.